title: [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
abstract: Since 01.07.1993 to 30.09.2004, 675 children with ALL-SR were diagnosed and treated according to the modified ALL-BFM 90 protocol. Subject to statistical analysis (Kaplan-Meier method) were thus 197 children with ALL-SR treated with HD-MTX in a dose 5.0g/ m2. Among them, 21 patients failed to respond to therapy: 2 (1.0%) early deaths, 2 (1.0%) deaths during I complete remission, 16 (8.2%) relapses, 1 (0.5%) second neoplasm. Relapses occured: 12 (6.2%) in bone marrow, 2 (1.0%) in central nervous system, 1 (0.5%) in testicle and in 1 (0.5%) child combined relapse was observed. Probability rates for 11-year event free survival (EFS) was 0.80 (0.03). Application of high dose of methotrexate is safety and effective in prevention of relapses, especially meningeal and testicular involvement.
authors.affiliation: Klinika Onkologii, Hematologii i Transplantologii Pediatrycznej, II Katedry Pediatrii AM 60-572 Poznań, ul. Szpitalna 27/33. kderwich@poczta.onet.pl
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Derwich
authors.forename: Jacek
authors.initials: J
authors.lastname: Wachowiaki
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Kaczmarek-Kanoldi
authors.forename: Anna
authors.initials: A
authors.lastname: Balcerska
authors.forename: Walentyna
authors.initials: W
authors.lastname: Balwierz
authors.forename: Alicja
authors.initials: A
authors.lastname: Chybicka
authors.forename: Jerzy R
authors.initials: JR
authors.lastname: Kowalczyk
authors.forename: Michał
authors.initials: M
authors.lastname: Matysiak
authors.forename: Teresa
authors.initials: T
authors.lastname: Jackowska
authors.forename: Danuta
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
authors.forename: Lidia
authors.initials: L
authors.lastname: Chełmecka-Hanuszewicz
authors.forename: Magdalena
authors.initials: M
authors.lastname: Cwiklińska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kołtan
authors.forename: Iwona
authors.initials: I
authors.lastname: Malinowska
authors.forename: Teresa
authors.initials: T
authors.lastname: Odój
authors.forename: Anna
authors.initials: A
authors.lastname: Płoszyńska
authors.forename: Monika
authors.initials: M
authors.lastname: Steczowicz
authors.forename: Violeta
authors.initials: V
authors.lastname: Wojciechowska
authors.forename: Anna
authors.initials: A
authors.lastname: Wójtowicz
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D011044:Poland / Q000453:epidemiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D008727:Methotrexate